| Assessment Status | Rapid Review complete |
| HTA ID | - |
| Drug | Certolizumab pegol |
| Brand | Cimzia® |
| Indication | For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 14/10/2019 |
| Rapid review completed | 14/11/2019 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that certolizumab pegol not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.